Education
About Us
Working with TipRanks
Follow Us
Merus NV (MRUS)
NASDAQ:MRUS
MRUS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$33.19 - $67.59
Previous CloseN/A
Volume56.75K
Average Volume (3M)655.72K
Market Cap
$4.81B
Enterprise Value$3.04B
Total Cash (Recent Filing)$710.22M
Total Debt (Recent Filing)$11.00M
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Oct 30, 2025EPS Estimate
-1.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.23
Shares Outstanding75,634,360
10 Day Avg. Volume558,734
30 Day Avg. Volume655,722
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.63
Enterprise Value/Revenue54.07
Enterprise Value/Gross Profit54.07
Enterprise Value/Ebitda-7.84
Forecast
1Y Price Target
$94.44Price Target Upside39.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Bulls Say, Bears Say
Bulls Say
Clinical DataInitial petosemtamab data in colorectal cancer and one or two Phase 3 readouts in Head and Neck Cancer offer significant potential upside for the stock.
Financial PositionThe strong ~$900MM cash position should provide runway.
Regulatory ApprovalPetosemtamab's potential approval via accelerated approval pathway in r/m Head and Neck Squamous Carcinoma could lead to significant stock upside.
Bears Say
Clinical ConcernsThe initial Phase I dose escalation study with petosemtamab showed no responses, which could be concerning for some investors.
Development ProgressThere are no meaningful updates or changes to timelines in the earnings release, suggesting stagnation in progress.
Financial PerformanceThe 2Q25 EPS at -$2.23 came in significantly higher than consensus of -$1.16 based on higher than expected R&D (-$21.5M) and SG&A (-$3.2M).
Merus News
MRUS FAQ
What was Merus NV’s price range in the past 12 months?
Merus NV lowest stock price was $33.19 and its highest was $67.59 in the past 12 months.
What is Merus NV’s market cap?
Merus NV’s market cap is $4.81B.
When is Merus NV’s upcoming earnings report date?
Merus NV’s upcoming earnings report date is Oct 30, 2025 which is in 67 days.
How were Merus NV’s earnings last quarter?
Merus NV released its earnings results on Aug 05, 2025. The company reported -$2.23 earnings per share for the quarter, missing the consensus estimate of -$1.165 by -$1.065.
Is Merus NV overvalued?
According to Wall Street analysts Merus NV’s price is currently Undervalued.
Does Merus NV pay dividends?
Merus NV does not currently pay dividends.
What is Merus NV’s EPS estimate?
Merus NV’s EPS estimate is -1.38.
How many shares outstanding does Merus NV have?
Merus NV has 75,634,360 shares outstanding.
What happened to Merus NV’s price movement after its last earnings report?
Merus NV reported an EPS of -$2.23 in its last earnings report, missing expectations of -$1.165. Following the earnings report the stock price went down -2.832%.
Which hedge fund is a major shareholder of Merus NV?
Currently, no hedge funds are holding shares in MRUS
Merus Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$94.44 (39.93% Upside)
$94.44 (39.93% Upside)
Blogger Sentiment
Bullish
MRUS Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 742.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
24.43%
12-Months-Change
Fundamentals
Return on Equity
-48.54%
Trailing 12-Months
Asset Growth
9.86%
Trailing 12-Months
Company Description
Merus NV
Merus (MRUS) is a clinical-stage biopharmaceutical company focused on the development of innovative antibody therapeutics for the treatment of cancer. The company is primarily engaged in the discovery and development of bispecific antibodies, which are designed to engage multiple targets in the tumor microenvironment, thereby enhancing the therapeutic efficacy against various cancer types. Merus operates within the biotechnology sector and aims to bring its proprietary antibody-based treatments to market through rigorous clinical trials and collaborations with other pharmaceutical companies.
MRUS Stock 12 Month Forecast
Average Price Target
$94.44
▲(39.93% Upside)
Technical Analysis
PTC Therapeutics
―
Zai Lab
―
Krystal Biotech
―
Akero Therapeutics
―
Avidity Biosciences
―
Ownership Overview
0.15% Insiders
18.52% Mutual Funds
61.07% Other Institutional Investors
18.30% Public Companies and
Individual Investors